These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12229255)

  • 41. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
    Fonarow GC; Lukas MA; Robertson M; Colucci WS; Dargie HJ
    Am Heart J; 2007 Oct; 154(4):637-44. PubMed ID: 17892984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carvedilol [Coreg].
    Kukin M
    Compr Ther; 1997 Sep; 23(9):617-20. PubMed ID: 9285163
    [No Abstract]   [Full Text] [Related]  

  • 43. Carvedilol for heart failure, with care.
    Cleland JG; Swedberg K
    Lancet; 1996 May; 347(9010):1199-201. PubMed ID: 8622445
    [No Abstract]   [Full Text] [Related]  

  • 44. Carvedilol: the new role of beta blockers in congestive heart failure.
    Vanderhoff BT; Ruppel HM; Amsterdam PB
    Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials.
    Doughty RN; Rodgers A; Sharpe N; MacMahon S
    Eur Heart J; 1997 Apr; 18(4):560-5. PubMed ID: 9129883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beta blockers: are they difficult to use in heart failure patients?
    Conti CR
    Clin Cardiol; 1999 Apr; 22(4):255-6. PubMed ID: 10198734
    [No Abstract]   [Full Text] [Related]  

  • 47. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT).
    Torp-Pedersen C; Køber L; Ball S; Hall A; Brendorp B; Ottesen M; Berning J; Jensen G; Hampton J; Zilles P; Eberle S; Carlsen J
    Eur J Heart Fail; 2002 Aug; 4(4):495-9. PubMed ID: 12167390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
    Remme WJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):99-101. PubMed ID: 16025226
    [No Abstract]   [Full Text] [Related]  

  • 49. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
    Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
    Talbert RL
    Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
    Kopecky SL
    Am J Cardiol; 2006 Oct; 98(8):1115-9. PubMed ID: 17027583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Role of beta-blockers in the treatment of chronic heart heart failure].
    Czuriga I; Edes I
    Orv Hetil; 2001 Sep; 142(37):2005-12. PubMed ID: 11582731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 54. [Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions].
    Pickl S
    Fortschr Med; 1997 Apr; 115(11):22. PubMed ID: 9221239
    [No Abstract]   [Full Text] [Related]  

  • 55. Beta-blocker therapy for heart failure: the standard of care.
    Cesario DA; Fonarow GC
    Rev Cardiovasc Med; 2002; 3(1):14-21. PubMed ID: 12439350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-blockers in heart failure: how far have we progressed?
    Adams KF
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):7-15. PubMed ID: 19667603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
    Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
    Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
    Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
    Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
    Nul D; Zambrano C; Diaz A; Ferrante D; Varini S; Soifer S; Grancelli H; Doval H;
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):125-34. PubMed ID: 16025231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Heart failure symptoms despite normal pump function. Beta blockers also improve diastole].
    MMW Fortschr Med; 2003 Jun; 145(26):58. PubMed ID: 12916341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.